NYSE:GSK - GlaxoSmithKline Stock Price, Price Target & More

$39.79 +0.67 (+1.71 %)
(As of 04/26/2018 09:06 AM ET)
Previous Close$39.12
Today's Range$39.79 - $39.79
52-Week Range$34.52 - $44.53
Volume25,368 shs
Average Volume3.95 million shs
Market Capitalization$100.76 billion
P/E Ratio13.58
Dividend Yield6.36%
Beta0.84

About GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline logoGlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:GSK
CUSIPN/A
Phone44-20-8047-5000

Debt

Debt-to-Equity Ratio4.09%
Current Ratio0.60%
Quick Ratio0.39%

Price-To-Earnings

Trailing P/E Ratio13.58
Forward P/E Ratio13.58
P/E Growth2.11

Sales & Book Value

Annual Sales$38.89 billion
Price / Sales2.54
Cash Flow$3.7573 per share
Price / Cash10.59
Book Value$1.81 per share
Price / Book21.98

Profitability

EPS (Most Recent Fiscal Year)$2.88
Net Income$1.97 billion
Net Margins4.97%
Return on Equity130.63%
Return on Assets10.28%

Miscellaneous

Employees99,827
Outstanding Shares2,479,430,000

How to Become a New Pot Stock Millionaire

GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Wednesday, February 7th. Investors of record on Friday, February 23rd will be paid a dividend of $0.633 per share on Thursday, April 12th. This represents a $2.53 dividend on an annualized basis and a yield of 6.47%. The ex-dividend date of this dividend is Thursday, February 22nd. This is a positive change from GlaxoSmithKline's previous quarterly dividend of $0.50. View GlaxoSmithKline's Dividend History.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline (NYSE:GSK) issued its earnings results on Wednesday, April, 25th. The pharmaceutical company reported $0.68 EPS for the quarter, missing the consensus estimate of $0.70 by $0.02. The pharmaceutical company had revenue of $10.04 billion for the quarter, compared to analysts' expectations of $10.26 billion. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. View GlaxoSmithKline's Earnings History.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for GlaxoSmithKline.

What price target have analysts set for GSK?

13 analysts have issued 12-month price targets for GlaxoSmithKline's shares. Their forecasts range from $35.85 to $40.00. On average, they anticipate GlaxoSmithKline's stock price to reach $38.6167 in the next twelve months. View Analyst Ratings for GlaxoSmithKline.

Who are some of GlaxoSmithKline's key competitors?

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the folowing people:
  • Ms. Emma Walmsley, Chief Exec. Officer & Director (Age 48)
  • Mr. Simon P. Dingemans, Chief Financial Officer & Exec. Director (Age 54)
  • Dr. Patrick J. T. Vallance, Pres of R&D and Exec. Director (Age 57)
  • Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 55)
  • Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 56)

Has GlaxoSmithKline been receiving favorable news coverage?

Media coverage about GSK stock has trended somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. GlaxoSmithKline earned a daily sentiment score of 0.09 on Accern's scale. They also assigned news coverage about the pharmaceutical company an impact score of 46.55 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $39.12.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $100.76 billion and generates $38.89 billion in revenue each year. The pharmaceutical company earns $1.97 billion in net income (profit) each year or $2.88 on an earnings per share basis. GlaxoSmithKline employs 99,827 workers across the globe.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]


MarketBeat Community Rating for GlaxoSmithKline (GSK)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  382 (Vote Outperform)
Underperform Votes:  713 (Vote Underperform)
Total Votes:  1,095
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GlaxoSmithKline (NYSE:GSK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
13 Wall Street analysts have issued ratings and price targets for GlaxoSmithKline in the last 12 months. Their average twelve-month price target is $38.6167, suggesting that the stock has a possible downside of 2.95%. The high price target for GSK is $40.00 and the low price target for GSK is $35.85. There are currently 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.382.312.252.21
Ratings Breakdown: 0 Sell Rating(s)
8 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
9 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
8 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
7 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $38.6167$38.2125$37.7125$43.50
Price Target Upside: 2.95% downside3.95% upside0.57% upside13.90% upside

GlaxoSmithKline (NYSE:GSK) Consensus Price Target History

Price Target History for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE:GSK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2018Deutsche BankReiterated RatingNeutralLowView Rating Details
4/4/2018BNP ParibasUpgradeNeutral -> OutperformMediumView Rating Details
3/22/2018Morgan StanleyUpgradeUnderweight -> Equal WeightMediumView Rating Details
2/15/2018CowenReiterated RatingHold$40.00LowView Rating Details
2/9/2018Kepler Capital MarketsUpgradeReduce -> HoldLowView Rating Details
2/5/2018JPMorgan ChaseReiterated RatingNeutralHighView Rating Details
1/16/2018BarclaysUpgradeEqual Weight -> OverweightLowView Rating Details
1/15/2018UBSReiterated RatingBuyMediumView Rating Details
11/30/2017ArgusLower Price TargetBuy$40.00LowView Rating Details
11/6/2017InvestecDowngradeBuy -> HoldN/AView Rating Details
10/26/2017Bank of AmericaDowngradeBuy -> NeutralN/AView Rating Details
7/27/2017CitigroupReiterated RatingNeutralLowView Rating Details
5/26/2017Berenberg BankUpgradeHold -> BuyLowView Rating Details
4/5/2017Exane BNP ParibasUpgradeUnderperform -> NeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
2/19/2017Jefferies GroupReiterated RatingBuyN/AView Rating Details
12/27/2016Goldman SachsReiterated RatingBuyN/AView Rating Details
10/26/2016Beaufort SecuritiesReiterated RatingBuyN/AView Rating Details
9/23/2016Piper JaffrayInitiated CoverageOverweightN/AView Rating Details
8/17/2016Shore CapitalReiterated RatingHoldN/AView Rating Details
5/5/2016Oddo SecuritiesUpgradeReduce -> BuyN/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

GlaxoSmithKline (NYSE:GSK) Earnings History and Estimates Chart

Earnings by Quarter for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE:GSK) Earnings Estimates

2018 EPS Consensus Estimate: $3.06
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.69$0.70$0.70
Q2 20181$0.82$0.82$0.82
Q3 20181$0.86$0.86$0.86
Q4 20181$0.68$0.68$0.68

GlaxoSmithKline (NYSE GSK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2018        
4/25/20183/31/2018$0.70$0.68$10.2638 billion$10.0443 billionViewN/AView Earnings Details
2/7/2018n/a$0.69$0.72$9.8910 billion$10.1409 billionViewN/AView Earnings Details
10/25/2017Q3 2017$0.84$0.85$10.2189 billion$10.2634 billionViewN/AView Earnings Details
7/26/20176/30/2017$0.68$0.70$9.5216 billion$9.3597 billionViewN/AView Earnings Details
4/26/20173/31/2017$0.62$0.62$9.0867 billion$9.23 billionViewN/AView Earnings Details
2/8/201712/31/2016$0.57$0.65$9.2133 billion$9.4307 billionViewListenView Earnings Details
10/26/2016Q316$0.7730$0.83$8.9199 billion$9.9027 billionViewListenView Earnings Details
7/27/2016Q2 2016$0.55$0.70$8.3481 billion$9.2150 billionViewN/AView Earnings Details
4/27/2016Q1 2016$0.60$0.57$8.5866 billion$8.9235 billionViewN/AView Earnings Details
2/3/2016Q4 2015$0.52$0.55$9.3563 billion$9.6170 billionViewN/AView Earnings Details
10/28/2015Q3$0.60$0.71$6.0708 billion$6.1270 billionViewN/AView Earnings Details
7/29/2015Q215$0.4970$0.53$9.1446 billion$9.0198 billionViewN/AView Earnings Details
5/6/2015Q115$0.55$0.48$8.5525 billion$8.5123 billionViewN/AView Earnings Details
2/4/2015Q414$0.86$0.82$6.1427 billion$6.1860 billionViewN/AView Earnings Details
10/22/2014Q314$0.79$0.90$9.7556 billion$9.1195 billionViewListenView Earnings Details
7/23/2014Q114$0.71$0.65$10.1307 billion$9.4721 billionViewN/AView Earnings Details
4/30/2014Q413$0.72$0.70$10.3571 billion$9.4402 billionViewN/AView Earnings Details
2/5/2014Q4$0.30$0.30$6.8377 billion$6.9060 billionViewN/AView Earnings Details
10/23/2013Q313$0.31$10.31 billion$10.09 billionViewN/AView Earnings Details
7/24/2013$0.26$0.26$6.6180 billionViewN/AView Earnings Details
4/25/2013Q1 2013$0.77$0.82$10.1273 billion$9.8746 billionViewN/AView Earnings Details
2/6/2013Q4 2012$0.96$1.04ViewN/AView Earnings Details
10/31/2012Q3 2012$0.89$0.85ViewN/AView Earnings Details
7/25/2012Q2 2012$0.84$0.82ViewN/AView Earnings Details
4/25/2012$0.29$0.2730ViewN/AView Earnings Details
2/7/2012$0.30$0.2840ViewN/AView Earnings Details
10/26/2011Q3 2011$0.90$0.89ViewN/AView Earnings Details
7/26/2011Q2 2011$0.77$0.81ViewN/AView Earnings Details
4/27/2011Q1 2011$1.00$1.02ViewN/AView Earnings Details
2/3/2011Q4 2010$0.88$0.91ViewN/AView Earnings Details
7/21/2010Q2 2010$0.88$0.10ViewN/AView Earnings Details
4/28/2010Q1 2010$0.86$0.93ViewN/AView Earnings Details
2/7/2010Q4 2009$1.12$1.14ViewN/AView Earnings Details
11/2/2009Q3 2009$0.96$0.93ViewN/AView Earnings Details
7/22/2009Q2 2009$0.86$1.02ViewN/AView Earnings Details
2/5/2009Q4 2008$0.80$0.81ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

GlaxoSmithKline (NYSE:GSK) Dividend Information

GlaxoSmithKline pays an annual dividend of $2.59 per share, with a dividend yield of 6.51%. GSK's most recent quarterly dividend payment was Thursday, April 12. GlaxoSmithKline pays out 89.93% of its earnings out as a dividend.
Most Recent Dividend:4/12/2018
Annual Dividend:$2.59
Dividend Yield:6.51%
Dividend Growth:-8.90% (3 Year Average)
Payout Ratio:89.93% (Trailing 12 Months of Earnings)
88.40% (Based on This Year's Estimates)
83.55% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE:GSK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/7/2018Quarterly$0.63306.48%2/22/20182/23/20184/12/2018
10/26/2017quarterly$0.50375.51%11/9/201711/10/20171/11/2018
7/26/2017Quarterly$0.49104.88%8/9/20178/11/201710/12/2017
4/26/2017quarterly$0.48304.79%5/10/20175/12/20177/13/2017
2/8/2017quarterly$0.57105.76%2/22/20172/24/20174/13/2017
10/26/2016$0.459011/2/201611/4/20161/12/2017
7/27/2016$0.49408/10/20168/12/201610/13/2016
4/28/2016$0.54905/11/20165/13/20167/14/2016
10/28/2015$0.577011/10/201511/13/20151/14/2016
5/7/2015quarterly$0.57695.22%5/13/20155/15/20157/9/2015
2/5/2015quarterly$0.69526.05%2/18/20152/20/20154/9/2015
10/23/2014quarterly$0.61305.41%11/5/201411/7/20141/8/2015
7/24/2014quarterly$0.64825.18%8/6/20148/8/201410/2/2014
5/1/2014quarterly$0.644.62%5/14/20145/16/20147/10/2014
2/5/2014$0.752/19/20142/21/20144/10/2014
2/6/2014quarterly$0.74965.73%2/19/20142/21/20144/10/2014
10/24/2013quarterly$0.61614.76%11/13/201311/15/20131/9/2014
7/25/2013quarterly$0.55324.27%8/7/20138/9/201310/3/2013
4/25/2013quarterly$0.55024.25%5/8/20135/10/20137/11/2013
2/7/2013quarterly$0.06900.61%2/20/20132/22/20134/11/2013
(Data available from 1/1/2013 forward)

Insider Trades

GlaxoSmithKline (NYSE GSK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 10.96%
Insider Trading History for GlaxoSmithKline (NYSE:GSK)
Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE GSK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/6/2017Plc GlaxosmithklineMajor ShareholderBuy428,571$14.00$5,999,994.00View SEC Filing  
10/24/2016Plc GlaxosmithklineMajor ShareholderBuy66,500$14.00$931,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

GlaxoSmithKline (NYSE GSK) News Headlines

Source:
DateHeadline
GSK Tries to Fix Pharma on a BudgetGSK Tries to Fix Pharma on a Budget
www.bloomberg.com - April 26 at 8:50 AM
Currency and pricing squeeze GlaxoSmithKline as new shingles vaccine shinesCurrency and pricing squeeze GlaxoSmithKline as new shingles vaccine shines
www.cnbc.com - April 25 at 4:58 PM
Glaxo's Shingles Vaccine 'Encouraging' But Shares Dip On Quarterly LagGlaxo's Shingles Vaccine 'Encouraging' But Shares Dip On Quarterly Lag
finance.yahoo.com - April 25 at 4:58 PM
Analysts’ Views on Sanofi, Pre-1Q18 Earnings ReleaseAnalysts’ Views on Sanofi, Pre-1Q18 Earnings Release
finance.yahoo.com - April 25 at 4:58 PM
Stronger pound weighs on revenues at drugmaker GSKStronger pound weighs on revenues at drugmaker GSK
finance.yahoo.com - April 25 at 4:58 PM
GlaxoSmithKline (GSK) Releases  Earnings Results, Misses Estimates By $0.01 EPSGlaxoSmithKline (GSK) Releases Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - April 25 at 2:54 PM
GlaxoSmithKline plc Shares Sink on Q1 Earnings MissGlaxoSmithKline plc Shares Sink on Q1 Earnings Miss
investorplace.com - April 25 at 12:33 PM
Stronger pound hinders GlaxoSmithKlineStronger pound hinders GlaxoSmithKline
www.ft.com - April 25 at 9:11 AM
Currency and pricing squeeze GSK as new shingles vaccine shinesCurrency and pricing squeeze GSK as new shingles vaccine shines
finance.yahoo.com - April 25 at 9:11 AM
BRIEF-Glaxosmithkline Says FDA Approves Expanded Indication For Trelegy Ellipta In The USBRIEF-Glaxosmithkline Says FDA Approves Expanded Indication For Trelegy Ellipta In The US
www.reuters.com - April 24 at 4:55 PM
Form 6-K GLAXOSMITHKLINE PLC For: Apr 24Form 6-K GLAXOSMITHKLINE PLC For: Apr 24
www.streetinsider.com - April 24 at 4:55 PM
Ozempic Could Be Potential Driver for Novo Nordisk in 2018Ozempic Could Be Potential Driver for Novo Nordisk in 2018
finance.yahoo.com - April 24 at 4:55 PM
Form 6-K GLAXOSMITHKLINE PLC For: Apr 20Form 6-K GLAXOSMITHKLINE PLC For: Apr 20
www.streetinsider.com - April 20 at 5:02 PM
What's in the Cards for Glaxo (GSK) This Earnings Season?What's in the Cards for Glaxo (GSK) This Earnings Season?
finance.yahoo.com - April 20 at 5:02 PM
Sanofi to Divest European Generic Unit, Streamline BusinessSanofi to Divest European Generic Unit, Streamline Business
finance.yahoo.com - April 19 at 5:22 PM
GlaxoSmithKline (GSK) Downgraded to "Hold" at Zacks Investment ResearchGlaxoSmithKline (GSK) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 19 at 12:49 PM
GlaxoSmithKline (GSK) Scheduled to Post Quarterly Earnings on WednesdayGlaxoSmithKline (GSK) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 19 at 8:47 AM
GSK grabs Roche cancer expert to lead pharma pipeline dealsGSK grabs Roche cancer expert to lead pharma pipeline deals
finance.yahoo.com - April 18 at 4:58 PM
Novartis’s 1Q18 Estimates: Expectations for AlconNovartis’s 1Q18 Estimates: Expectations for Alcon
finance.yahoo.com - April 18 at 4:58 PM
GSK flags pharma M&A ambitions by poaching Roche deal-makerGSK flags pharma M&A ambitions by poaching Roche deal-maker
finance.yahoo.com - April 18 at 4:58 PM
GlaxoSmithKline (GSK) Upgraded to "Buy" by Zacks Investment ResearchGlaxoSmithKline (GSK) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 18 at 12:50 PM
Form 6-K GLAXOSMITHKLINE PLC For: Apr 17Form 6-K GLAXOSMITHKLINE PLC For: Apr 17
www.streetinsider.com - April 17 at 5:13 PM
GlaxoSmithKline (GSK) Lowered to Strong Sell at BidaskClubGlaxoSmithKline (GSK) Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - April 16 at 8:40 PM
Jefferies Group Weighs in on GlaxoSmithKlines Q1 2018 Earnings (GSK)Jefferies Group Weighs in on GlaxoSmithKline's Q1 2018 Earnings (GSK)
www.americanbankingnews.com - April 16 at 1:32 AM
GlaxoSmithKline (GSK) Receives Consensus Recommendation of "Hold" from AnalystsGlaxoSmithKline (GSK) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 15 at 5:30 PM
GSK divests its rare disease gene therapy portfolioGSK divests its rare disease gene therapy portfolio
finance.yahoo.com - April 12 at 5:01 PM
GlaxoSmithKline (GSK) Lowered to "Hold" at Zacks Investment ResearchGlaxoSmithKline (GSK) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 11 at 10:27 AM
New GSK shingles vaccine off to strong start in key US marketNew GSK shingles vaccine off to strong start in key US market
www.reuters.com - April 10 at 4:58 PM
New GSK shingles vaccine off to strong start in key U.S. marketNew GSK shingles vaccine off to strong start in key U.S. market
www.cnbc.com - April 10 at 3:07 PM
GlaxoSmithKlines share price is rising. Is it time to buy?GlaxoSmithKline's share price is rising. Is it time to buy?
www.fool.co.uk - April 9 at 5:05 PM
Assessing the Performance of Novartis Stock in 1Q18Assessing the Performance of Novartis Stock in 1Q18
finance.yahoo.com - April 9 at 5:05 PM
GSK’s Acquisition of Novartis’ Consumer Healthcare Joint VentureGSK’s Acquisition of Novartis’ Consumer Healthcare Joint Venture
finance.yahoo.com - April 9 at 5:05 PM
GlaxoSmithKlines (GSK) "Neutral" Rating Reaffirmed at Deutsche BankGlaxoSmithKline's (GSK) "Neutral" Rating Reaffirmed at Deutsche Bank
www.americanbankingnews.com - April 9 at 8:25 AM
Why I believe the GlaxoSmithKline share price is now too cheap to ignoreWhy I believe the GlaxoSmithKline share price is now too cheap to ignore
www.fool.co.uk - April 8 at 9:01 AM
GlaxoSmithKline plc isnt the only pharma stock Id buy todayGlaxoSmithKline plc isn't the only pharma stock I'd buy today
www.fool.co.uk - April 6 at 5:07 PM
JPMorgan Chase Reaffirms "Neutral" Rating for GlaxoSmithKline (GSK)JPMorgan Chase Reaffirms "Neutral" Rating for GlaxoSmithKline (GSK)
www.americanbankingnews.com - April 6 at 12:28 AM
GlaxoSmithKline (GSK) Stock Rating Lowered by Zacks Investment ResearchGlaxoSmithKline (GSK) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 5 at 7:26 PM
Lilly's Cyramza Shows Survival Benefit in Liver Cancer StudyLilly's Cyramza Shows Survival Benefit in Liver Cancer Study
finance.yahoo.com - April 5 at 4:58 PM
3 High-Yield Stocks That Have Bucked the Stock Market Correction3 High-Yield Stocks That Have Bucked the Stock Market Correction
finance.yahoo.com - April 5 at 9:35 AM
GlaxoSmithKline (GSK) Downgraded to "Neutral" at Bank of AmericaGlaxoSmithKline (GSK) Downgraded to "Neutral" at Bank of America
www.americanbankingnews.com - April 4 at 9:36 PM
GlaxoSmithKline (GSK) Cut to "Hold" at Zacks Investment ResearchGlaxoSmithKline (GSK) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 4 at 12:44 PM
GlaxoSmithKline (GSK) Upgraded at BNP ParibasGlaxoSmithKline (GSK) Upgraded at BNP Paribas
www.americanbankingnews.com - April 4 at 9:30 AM
Why GlaxoSmithKline Stock Rose in the Week Ended March 29Why GlaxoSmithKline Stock Rose in the Week Ended March 29
finance.yahoo.com - April 3 at 5:11 PM
GlaxoSmithKline (GSK) Upgraded by Zacks Investment Research to "Buy"GlaxoSmithKline (GSK) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 3 at 12:44 PM
How Eli Lilly’s Neuroscience Products Performed in 4Q17How Eli Lilly’s Neuroscience Products Performed in 4Q17
finance.yahoo.com - April 2 at 9:34 AM
 Brokerages Expect GlaxoSmithKline (GSK) Will Post Earnings of $0.73 Per Share Brokerages Expect GlaxoSmithKline (GSK) Will Post Earnings of $0.73 Per Share
www.americanbankingnews.com - April 1 at 11:22 AM
Better Buy: Celgene Corporation vs. Gilead SciencesBetter Buy: Celgene Corporation vs. Gilead Sciences
finance.yahoo.com - March 30 at 8:55 AM
Nucala (mepolizumab; GlaxoSmithKline) Drug Analysis 2018 - ResearchAndMarkets.comNucala (mepolizumab; GlaxoSmithKline) Drug Analysis 2018 - ResearchAndMarkets.com
www.businesswire.com - March 29 at 4:59 PM
GS Mortgage Securities Trust 2017-GS5 -- Moodys Affirms Seven Classes of GSMS 2017-GS5GS Mortgage Securities Trust 2017-GS5 -- Moody's Affirms Seven Classes of GSMS 2017-GS5
finance.yahoo.com - March 29 at 4:59 PM
GlaxoSmithKline (GSK) Rating Lowered to Hold at Zacks Investment ResearchGlaxoSmithKline (GSK) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:44 PM

SEC Filings

GlaxoSmithKline (NYSE:GSK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

GlaxoSmithKline (NYSE:GSK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

GlaxoSmithKline (NYSE GSK) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.